TY - JOUR
T1 - Unveiling abrocitinib
T2 - A thorough examination of the 2022 USFDA-approved treatment for atopic dermatitis (AD)
AU - Grajales, Daniela Bermeo
AU - Sewdat, Nermala
AU - Leo, Ryan
AU - Kar, Supratik
N1 - Publisher Copyright:
© 2023 The Authors
PY - 2023/12
Y1 - 2023/12
N2 - Abrocitinib stands as a targeted therapy, functioning as an inhibitor of Janus kinase (JAK) 1. This pharmaceutical advancement has been meticulously crafted to address the challenges of moderate to severe atopic dermatitis (AD), a prevalent skin ailment in developed nations. Introduced in 2022, Abrocitinib emerged as a cutting-edge addition to its therapeutic category, gaining approval for utilization within the United States. Diverging from its predecessors in the realm of moderate to severe AD treatment, Abrocitinib distinguishes itself through its heightened specificity. Moreover, its tablet formulation facilitates straightforward administration, offering diverse dosage options. An additional noteworthy feature is its applicability to individuals aged 12 and above, making it an option for alleviating symptoms in this demographic. Within this comprehensive assessment, key aspects such as the biological target of the drug, developmental strategies, mode of operation, pharmacokinetics, pharmacodynamics, clinical trial insights, contraindications, potential interactions with other medications, and adverse reactions are examined. In light of the overarching perspective and available clinical evidence, Abrocitinib emerges as a promising orally bioavailable therapeutic, authorized for treating AD. Notably, it gained its initial approval in Japan for patients aged 12 years and older, marking a significant advancement in the realm of dermatological care.
AB - Abrocitinib stands as a targeted therapy, functioning as an inhibitor of Janus kinase (JAK) 1. This pharmaceutical advancement has been meticulously crafted to address the challenges of moderate to severe atopic dermatitis (AD), a prevalent skin ailment in developed nations. Introduced in 2022, Abrocitinib emerged as a cutting-edge addition to its therapeutic category, gaining approval for utilization within the United States. Diverging from its predecessors in the realm of moderate to severe AD treatment, Abrocitinib distinguishes itself through its heightened specificity. Moreover, its tablet formulation facilitates straightforward administration, offering diverse dosage options. An additional noteworthy feature is its applicability to individuals aged 12 and above, making it an option for alleviating symptoms in this demographic. Within this comprehensive assessment, key aspects such as the biological target of the drug, developmental strategies, mode of operation, pharmacokinetics, pharmacodynamics, clinical trial insights, contraindications, potential interactions with other medications, and adverse reactions are examined. In light of the overarching perspective and available clinical evidence, Abrocitinib emerges as a promising orally bioavailable therapeutic, authorized for treating AD. Notably, it gained its initial approval in Japan for patients aged 12 years and older, marking a significant advancement in the realm of dermatological care.
KW - Abrocitinib
KW - Atopic dermatitis
KW - Clinical trials
KW - JAK1
KW - PK/PD
KW - US FDA
UR - http://www.scopus.com/inward/record.url?scp=85174804000&partnerID=8YFLogxK
U2 - 10.1016/j.medidd.2023.100161
DO - 10.1016/j.medidd.2023.100161
M3 - Review article
AN - SCOPUS:85174804000
SN - 2590-0986
VL - 20
JO - Medicine in Drug Discovery
JF - Medicine in Drug Discovery
M1 - 100161
ER -